Navigation Links
Bionovo to Advance Menerba to Phase 3 Clinical Testing in Europe
Date:7/29/2010

EMERYVILLE, Calif., July 29 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today that it has received final guidance from the European Medicines Agency (EMA) in order to advance Menerba, the company's lead drug candidate for menopausal symptoms, to Phase 3 clinical trials in Europe. The guidance defines the clinical and regulatory pathway to a European marketing authorization for Menerba.

"We are pleased with the outcome of our Scientific Advice meetings with the European Medicines Agency. We are eager to put this guidance to use and to start our late stage pivotal studies for Menerba," said Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer.

"There are 37 million menopausal women in Europe and, with a European marketing authorization, we expect the European market demand to be strong for a safe and efficacious alternative to hormone therapy for the treatment of hot flashes," said Mary Tagliaferri, M.D., Bionovo's President and Chief Medical Officer.

The Company has also had a meeting with the U.S. Food and Drug Administration (FDA) on the development of Menerba in the U.S., and looks forward to providing more details when the minutes of the meeting are released.

About Menerba

Menerba is an oral, botanically-derived drug candidate designed for the safe, effective treatment of vasomotor symptoms (hot flashes) associated with menopause. Menerba is an estrogen receptor beta (ER-beta) selective drug, developed as a safer alternative to the products currently
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bionovo, Inc. to Announce Second Quarter Fiscal Year 2010 Financial Results on Wednesday, August 4, 2010
2. Bionovo Announces a $15 Million At-The-Market Firm Commitment Financing Agreement
3. Bionovo Announces 2009 Highlights and Year-End Financial Results
4. Bionovo, Inc. to Announce Fourth Quarter and Fiscal Year 2009 Financial Results on Monday, March 15, 2010
5. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
6. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
7. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2009 Financial Results on Thursday, November 5, 2009
8. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
9. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
10. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
11. Bionovo Announces First Quarter 2009 Highlights and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... and NEW YORK , ... of the executive management team of Caremark Rx, ... Media ( www.pbm365.com ).  PBM365 is the leading independent ... reporting, insight, analysis and opinion on the pharmacy ... will provide insightful and timely coverage of, and context ...
(Date:7/29/2014)... 2014 According to a new ... Fixation Devices Market - Global Forecast, Market Share, Size, ... orthopedic trauma fixation devices market is estimated at USD ... at a CAGR of 7.2% from 2014 to 2019, ... in 2020. Browse the Orthopedic Trauma Fixation ...
(Date:7/29/2014)... -- Research and Markets has announced the ... report to their offering. ... a medical device used to provide medication or assist ... cannot achieve adequate oxygen levels to maintain life. Patients ... and ARDS require the need of respiratory devices. The ...
Breaking Medicine Technology:Drew Crawford Announces Launch of PBM365 Media 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4Global Respiratory Devices Market 2014-2018 2
... May 19 A meta-analysis of approximately ... The Lancet on May 1, 2010 ... phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory enzyme, are associated ... in magnitude to that with non-HDL cholesterol or systolic ...
... SAN FRANCISCO , May 19 ... trials evaluating Ferring Pharmaceuticals, LYSTEDA™ (tranexamic acid) tablets, a ... with cyclic heavy menstrual bleeding (HMB), were presented at ... Clinical Meeting in San Francisco , May ...
Cached Medicine Technology:Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 3Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 2Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 3Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 4Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 5Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 6
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... the author of this program claims that he cured his ... the author decided to share part of his experience. ... nasal polys permanently and naturally in just 4 days. Since ... share it with sufferers from all around the world. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip indicates ... new method was created for any sufferer who is looking ... , The author of the new program, Sarah Summer, says ... actually suffered from yeast infection, too. Actually, this is the ... for this problem. , The Natural Cure for ...
(Date:7/29/2014)... For numerous women from all over the world, finding ... being quite hard. Well, the author of the Make Him ... can help all these women. This is the formula that ... and attention every day. , Daily Gossip reveals in ... Alex Carter who published a unique eBook to detail it. ...
(Date:7/29/2014)... Recent international changes to the ... Nurse Call Systems to be considered medical devices. ... Nurse Call Systems to be clinically regulated, audited ... reduces clinical risks, and is good news for ... and Clinical Risk Committee actively pursuing corporate governance. ...
(Date:7/29/2014)... Daily Gossip reveals in its review that the Tinnitus Miracle ... eliminate all the symptoms associated to this condition. , ... such as mild hearing loss, as well as headaches. The ... gone forever. , The method will lead to a cure ... says that at the end of the treatment, sufferers will ...
Breaking Medicine News(10 mins):Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2Health News:"Make Him Desire You" Review Reveals Unique Formula to Make Men Feel a Special Kind of Love 2Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 2Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 3Health News:NiQ Health Reveals the Extensive Use of Unregulated Medical Devices in Australian Hospitals 4Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2
... ,Using the male chromosome as a marker, researchers studying ... have discovered that the body can actively reshape the ... that the heart cannot repair itself and the finding ... realization that the body works to repair a damaged ...
... patients on long-term non-steroidal anti-inflammatory drug (NSAID) treatment ... can substantially reduce the risk of ulcer formation.// ... cent of H.pylori infections and reduced the six-month ... the control group to 12 per cent in ...
... say they have discovered molecules in the body ... free radicals.With further research, the research could potentially ... Oxidative damage has been linked with ailments such ... and diabetes, cancer and Alzheimer’s disease. ...
... a steroid nasal spray may relieve seasonal ... Dr. Robert Naclerio and colleagues from University ... nasal spray, with loratadine(Claritin),a nonsedating antihistamine, for ... , Participants who used the inhaled ...
... way to slow down the respiration rate. Just by practising ... can be slowed down and thereby calm the heart rhythm. ... ritual in the Catholic Church - and the benefits may ... Cleavland, recorded breathing rates during normal talking and recitation of ...
... from asthma, particularly women, may have an increased risk ... years, researchers studied almost 100,000 patients who had been ... showed any signs of cancer at their initial assessment. ... asthma diagnosis until the last day of the three-decade ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: